FibroGen, Inc. (0IL8.L)
USD 0.36
(3.62%)
USD 0.36
(3.62%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -281.81 Million USD | 10.57% |
| 2022 | -301.02 Million USD | -4.33% |
| 2021 | -288.53 Million USD | -50.37% |
| 2020 | -191.88 Million USD | -114.84% |
| 2019 | -89.31 Million USD | -3.02% |
| 2018 | -86.69 Million USD | 29.29% |
| 2017 | -122.6 Million USD | -128.52% |
| 2016 | -53.65 Million USD | 30.88% |
| 2015 | -77.62 Million USD | -54.93% |
| 2014 | -50.1 Million USD | -530.29% |
| 2013 | -7.94 Million USD | 70.8% |
| 2012 | -27.22 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -10.91 Million USD | 64.85% |
| 2024 Q1 | -31.06 Million USD | 42.68% |
| 2023 Q3 | -63.48 Million USD | 27.9% |
| 2023 Q4 | -54.19 Million USD | 14.63% |
| 2023 Q1 | -76.09 Million USD | -15.02% |
| 2023 Q2 | -88.04 Million USD | -15.71% |
| 2023 FY | -269.2 Million USD | 10.57% |
| 2022 Q4 | -66.15 Million USD | 29.37% |
| 2022 FY | -301.02 Million USD | -4.33% |
| 2022 Q3 | -93.65 Million USD | -19.73% |
| 2022 Q2 | -78.22 Million USD | -24.18% |
| 2022 Q1 | -62.99 Million USD | 53.42% |
| 2021 FY | -288.53 Million USD | -50.37% |
| 2021 Q2 | -133.83 Million USD | -90.03% |
| 2021 Q4 | -135.24 Million USD | -365.31% |
| 2021 Q3 | 50.97 Million USD | 138.09% |
| 2021 Q1 | -70.42 Million USD | -21.43% |
| 2020 FY | -191.88 Million USD | -114.84% |
| 2020 Q1 | -81.07 Million USD | 19.28% |
| 2020 Q2 | -85.13 Million USD | -5.01% |
| 2020 Q3 | 32.33 Million USD | 137.97% |
| 2020 Q4 | -57.99 Million USD | -279.4% |
| 2019 Q4 | -100.43 Million USD | -90.03% |
| 2019 FY | -89.31 Million USD | -3.02% |
| 2019 Q3 | -52.85 Million USD | -146.85% |
| 2019 Q2 | 112.81 Million USD | 330.98% |
| 2019 Q1 | -48.84 Million USD | -345.21% |
| 2018 Q3 | -42.77 Million USD | -84.04% |
| 2018 Q4 | 19.91 Million USD | 146.57% |
| 2018 Q1 | -40.59 Million USD | -70.51% |
| 2018 Q2 | -23.24 Million USD | 42.75% |
| 2018 FY | -86.69 Million USD | 29.29% |
| 2017 FY | -122.6 Million USD | -128.52% |
| 2017 Q3 | -36.01 Million USD | -14.67% |
| 2017 Q1 | -31.37 Million USD | -0.29% |
| 2017 Q2 | -31.4 Million USD | -0.12% |
| 2017 Q4 | -23.81 Million USD | 33.89% |
| 2016 FY | -53.65 Million USD | 30.88% |
| 2016 Q4 | -31.28 Million USD | -41.53% |
| 2016 Q3 | -22.1 Million USD | -183.37% |
| 2016 Q2 | 26.51 Million USD | 198.98% |
| 2016 Q1 | -26.78 Million USD | 44.71% |
| 2015 FY | -77.62 Million USD | -54.93% |
| 2015 Q4 | -48.44 Million USD | -10.69% |
| 2015 Q3 | -43.77 Million USD | -173.79% |
| 2015 Q2 | 59.31 Million USD | 232.63% |
| 2015 Q1 | -44.72 Million USD | 6.78% |
| 2014 Q2 | 49.17 Million USD | 446.14% |
| 2014 Q4 | -47.97 Million USD | -29.33% |
| 2014 Q3 | -37.09 Million USD | -175.44% |
| 2014 FY | -50.1 Million USD | -530.29% |
| 2014 Q1 | -14.2 Million USD | 43.07% |
| 2013 Q1 | -16.68 Million USD | 0.0% |
| 2013 Q3 | 41.17 Million USD | 650.19% |
| 2013 Q2 | -7.48 Million USD | 55.15% |
| 2013 Q4 | -24.95 Million USD | -160.61% |
| 2013 FY | -7.94 Million USD | 70.8% |
| 2012 FY | -27.22 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | -66.576% |
| Dynavax Technologies Corporation | -37.02 Million USD | -661.086% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -5248.548% |
| Perrigo Company plc | 151.9 Million USD | 285.527% |
| Illumina, Inc. | -1.06 Billion USD | 73.638% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 104.109% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 38.81% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 97.998% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 114.255% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -154.771% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 106.963% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -530.924% |
| Waters Corporation | 817.67 Million USD | 134.465% |
| Biogen Inc. | 1.29 Billion USD | 121.732% |
| Sangamo Therapeutics, Inc. | -274 Million USD | -2.85% |
| Evolus, Inc. | -49.23 Million USD | -472.411% |
| Adicet Bio, Inc. | -152.03 Million USD | -85.358% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -131.956% |
| bluebird bio, Inc. | -244.26 Million USD | -15.374% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -81.158% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 120.875% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -525.182% |
| Homology Medicines, Inc. | -48.25 Million USD | -484.012% |
| Geron Corporation | -193.94 Million USD | -45.307% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 0.128% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -283.453% |
| Myriad Genetics, Inc. | -123.7 Million USD | -127.821% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -179.504% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 45.31% |
| Zoetis Inc. | 3.06 Billion USD | 109.183% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -484.678% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 125.919% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 244.936% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 106.542% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -619.779% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 20.33% |
| Atara Biotherapeutics, Inc. | -276 Million USD | -2.105% |
| Verastem, Inc. | -92.08 Million USD | -206.041% |
| Nektar Therapeutics | -137.42 Million USD | -105.068% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -21.564% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -189.466% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | -5.224% |
| OPKO Health, Inc. | -157.02 Million USD | -79.476% |
| Exelixis, Inc. | 170.88 Million USD | 264.915% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 212.322% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 362.686% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -405.443% |
| uniQure N.V. | -282.87 Million USD | 0.373% |
| Imunon, Inc. | -21.03 Million USD | -1240.034% |
| Blueprint Medicines Corporation | -486.27 Million USD | 42.046% |
| Insmed Incorporated | -709.62 Million USD | 60.287% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 183.482% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 28.014% |
| TG Therapeutics, Inc. | 20.63 Million USD | 1465.846% |
| Incyte Corporation | 620.52 Million USD | 145.416% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 61.204% |